Ⓐ
PeptiBrief
Evidence Library
acute_human_inhalation_study · 2008

Inhalation of vasoactive intestinal peptide in pulmonary hypertension

Leuchte HH|Baumgartner RA|Nounou ME|Vogeser M|Neurohr C|Trautnitz M|Behr J · European Respiratory Journal
moderatePMID · 18978135Verified
View source
Plain-English summary

Inhaled synthetic VIP was assessed as a short-term pulmonary vasodilator in a small clinical study.

Population
Adults with chronic pulmonary hypertension
Intervention
Single inhaled dose of aviptadil
Outcomes measured
Pulmonary haemodynamics|Blood gases|Safety
Key findings
Supported acute pulmonary target engagement with limited evidence for lasting benefit.
Limitations
Small sample|Single-dose study|No long-term efficacy outcomes
Risk of bias
Moderate because of sample size and acute design.
Citation
Leuchte HH|Baumgartner RA|Nounou ME|Vogeser M|Neurohr C|Trautnitz M|Behr J (2008). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. European Respiratory Journal
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.